HR (p)† | FVC Decline | SSc, 74 patients | Progression-free Survival | FVC Decline | IPF, 58 patients | Progression-free Survival | ||
---|---|---|---|---|---|---|---|---|
DLCO Decline | Mortality | DLCO Decline | Mortality | |||||
IL-6 | 1.08 | 1.45 (0.003)†† | 1.18 | 1.26 (0.03) | 1.44 (0.009) | 1.50 (0.003)†† | 1.22 (0.06) | 1.32 (0.008) |
IL-8 | 1.1 | 1.03 | 0.98 | 1 | 1.13 | 1.2 (0.04) | 1.07 | 1.14 (0.05) |
CCL2 | 0.77 | 1.15 | 0.95 | 0.83 | 2.01 (0.04) | 2.05 (0.03) | 1.22 | 2.65 (< 0.001)†† |
IL-10 | 1.04 | 1.25 (0.09) | 1.02 | 1.07 | 1.32 | 1.45 | 1.56 (0.08) | 1.07 |
CXCL10 | 0.9 | 1.2 | 1.06 | 1.02 | 1.14 | 1.09 | 1.74 (0.04) | 1.37 (0.09) |
VEGF | 1.1 | 1.12 | 1.26 | 1.14 | 1.17 | 1.25 | 1.27 | 1.09 |
FGF2* | 0.92 | 2.28 (0.03) | 3.05 (0.02) | 1.6 | 1.12 | 1.68 | 1.67 | 1.05 |
CX3CL1* | 1.24 | 2.38 (0.02) | 1 | 1.45 | 1.31 | 1.7 | 2.02 | 1.03 |
↵† p values reported in parentheses when < 0.01.
↵†† p < 0.05 after Bonferroni correction.
↵* Analyzed as dichotomous variables. CCL2: chemokine (C-C motif) ligand 2; CXCL10: chemokine (C-X-C motif) ligand 10; VEGF: vascular endothelial growth factor; FGF2: fibroblast growth factor 2; CX3CL1: chemokine (C-X3-C motif) ligand 1; IPF: idiopathic pulmonary fibrosis; SSc: systemic sclerosis; FVC: forced vital capacity; IL: interleukin.